Association of gene expression signatures and mutational status of baseline tumors with response to glofitamab. (A) Bar plots show the distribution of COO classes in baseline biopsy samples (analyzed by RNA-sequencing) according to the best overall response (BOR) category (P = .9). (B) Bar plots represent the distribution of the BOR categories in tumor mutational burden (TMB) low subsets (<15 mutations/Mb) and high subsets (≥15 mutations/Mb), measured by targeted-sequencing in baseline biopsy samples (P = .95). Box plots show signature scores (RNA-sequencing) of baseline biopsy samples for CD8⁺ effector T cells (C), PD1 high (D), MYC (E), and TP53 (F) target genes in different BOR categories. Values above 0 indicate signature enrichments in each biopsy. (G) Bar plots represent distribution of the BOR categories in TP53 wild-type (WT) and mutant (mut) subsets measured by targeted-sequencing in baseline biopsy samples (P = .09). Statistical analyses in panels B to F were performed for CR vs PR/stable disease (SD)/progressive disease (PD) and adjusted for log(glofitamab dose) and IPI category. Data in panel A and panels C to F are generated from n = 35 patients with RNA-sequencing data, and in panels B and G from n = 33 patients with targeted sequencing data. ABC, activated B-cell; GCB, germinal center B-cell.